AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.16 |
Market Cap | 54.05M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.92 |
PE Ratio (ttm) | -0.55 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.49 |
Volume | 361,917 |
Avg. Volume (20D) | 1,948,496 |
Open | 2.29 |
Previous Close | 2.29 |
Day's Range | 2.11 - 2.30 |
52-Week Range | 0.87 - 12.85 |
Beta | undefined |
About OTLK
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...
Analyst Forecast
According to 6 analyst ratings, the average rating for OTLK stock is "Buy." The 12-month stock price forecast is $31.4, which is an increase of 1347.00% from the latest price.
Next Earnings Release
Analysts project revenue of $250.00K, reflecting a n/a YoY growth and earnings per share of -1.11, making a 38.75% increase YoY.